Items related to biologics will be added to the top of the list as they are posted on the site.
08/12/2026 Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products; Guidance for Industry 08/10/2026 August 7, 2026 Approval Letter - MRESVIA 08/07/2026 August 6, 2026 Approval Letter - YESCARTA 08/06/2026 August 6, 2026 Approval Letter - TUDRIQEV 08/06/2026 August 5, 2026 Approval Letter - MFLUSIVA 08/06/2026 FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in Biologics Draft agenda added08/03/2026 Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance of Industry Updated: August 3, 20267/31/2026 July 31, 2026 Approval Letter - Alphanate 7/31/2026 July 30, 2026 Approval Letter - ADACEL 07/31/2026 Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry 07/30/2026 SOPP 8401: Administrative Processing of Original Biologics License Applications (BLA) and New Drug Applications (NDA) 07/29/2026 July 29, 2026 Approval Letter - EZPLAZ 07/28/2026 July 27, 2026 Approval Letter - AREXVY 07/27/2026 Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, IRBs, and Clinical Investigators 07/27/2026 Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, IRBs, and Clinical Investigators 07/27/2026 Cancer Clinical Trial Eligibility Criteria: Performance Status; Guidance for Industry, IRBs, and Clinical Investigators 07/24/2026 BK261351- ADAMII CD34 System 07/23/2026 OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products Town Hall Transcript available07/23/2026 July 22, 2026 Approval Letter - FluMist 07/16/2026 SOPP 8795: Posting and Announcement of Premarket Approval Application and Humanitarian Device Exemption Approvals and Denials 07/15/2026 July 14, 2026 Approval Letter - HEXTEND HMW Hydroxyethel Starch (6%) 07/15/2026 FDA Roundtable: Strengthening the Supply Chain for Blood Manufacturing Date: September 29, 2026
Content current as of:
08/12/2026